Myocardial remodelling: pharmacological targets

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Heart failure remains a leading cause of mortality despite therapeutic advancements.
• Increasing lifespan highlights the need for effective treatments for cardiac remodelling.
• Existing therapies like ACE inhibitors and beta-blockers show partial reversibility of cardiac remodelling.

Purpose of the Study:

• To outline a therapeutic research strategy based on molecular mechanisms of cardiac remodelling.
• To evaluate emerging pharmacological interventions for heart failure.
• To challenge conventional views on cardiac hypertrophy and hormonal influences.

Main Methods:

• Review of recent advances in understanding molecular mechanisms of cardiac remodelling.
• Evaluation of novel therapeutic agents and targets in preclinical and clinical development.
• Critical analysis of current therapeutic paradigms and their underlying assumptions.

Main Results:

• Cardiac remodelling is not solely a detrimental process and may be partially reversible.
• Hormonal influences and inotropic interventions require re-evaluation in the context of cardiac remodelling.
• Emerging therapies targeting molecular pathways show promise for heart failure treatment.

Conclusions:

• A molecular-based strategy is crucial for developing effective heart failure therapies.
• Revisiting established concepts of cardiac hypertrophy and hormonal roles is necessary.
• Novel approaches including nitric oxide donors and apoptosis inhibitors offer new avenues for treatment.